The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge

被引：36
作者：
Temian, Daiana Cosmina [1 ,2 ]
Pop, Laura Ancuta [1 ]
Irimie, Alexandra Iulia [3 ]
Berindan-Neagoe, Ioana [1 ,4 ,5 ]
机构：
[1] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Fac Med, Cluj Napoca, Romania
[3] Iuliu Hatieganu Univ Med & Pharm, Dept Prosthet Dent & Dent Mat, Div Dent Propaedeut, Aesthet, 23 Marinescu St, Cluj Napoca 40015, Romania
[4] Iuliu Hatieganu Univ Med & Pharm, MedFUTURE Res Ctr Adv Med, Cluj Napoca, Romania
[5] Oncol Inst Prof Dr I Chiricuta, Dept Funct Genom & Expt Pathol, Cluj Napoca, Romania
来源：
JOURNAL OF BREAST CANCER | 2018年 / 21卷 / 03期
关键词：
Breast neoplasms; DNA methylation; Histone code; Triple negative breast neoplasms; Untranslated RNA; LONG NONCODING RNAS; HISTONE DEACETYLASE INHIBITORS; PREDICTS SENSITIVITY; MOLECULAR PORTRAITS; DOWN-REGULATION; AXON GUIDANCE; MUTANT P53; EXPRESSION; IDENTIFICATION; BROMODOMAIN;
D O I：
10.4048/jbc.2018.21.e41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies-the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis-DNA methylation, histone modifications, and noncoding RNAs-advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the epigenetic discoveries that have been made related to the triple-negative breast cancer.
引用
收藏
页码：233 / +
页数：16
相关论文
共 50 条
  • [31] Triple-Negative Breast Cancer: Current Data and Future Prospects
    de Nonneville, A.
    Goncalves, A.
    ONCOLOGIE, 2019, 21 (1-4) : 33 - 39
  • [32] Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology
    Abuhussein, Omar
    Yang, Jian
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1316 - 1325
  • [33] Molecular Classification of Triple-Negative Breast Cancer
    Ahn, Sung Gwe
    Kim, Seung Jun
    Kim, Cheungyeul
    Jeong, Joon
    JOURNAL OF BREAST CANCER, 2016, 19 (03) : 223 - 230
  • [34] Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer
    Ceprnja, Toni
    Tomic, Snjezana
    Balja, Melita Peric
    Marusic, Zlatko
    Blazicevic, Valerija
    Spagnoli, Giulio Cesare
    Juretic, Antonio
    Capkun, Vesna
    Vuger, Ana Tecic
    Pogorelic, Zenon
    Mrklic, Ivana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (08)
  • [35] Dysregulation of the epigenome in triple-negative breast cancers: Basal-like and claudin-low breast cancers express aberrant DNA hypermethylation
    Roll, J. Devon
    Rivenbark, Ashley G.
    Sandhu, Rupninder
    Parker, Joel S.
    Jones, Wendell D.
    Carey, Lisa A.
    Livasy, Chad A.
    Coleman, William B.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2013, 95 (03) : 276 - 287
  • [36] Mammography and ultrasound effective features in differentiating basal-like and normal-like subtypes of triple negative breast cancer
    Zeng, Zeng
    Hou, Chun Jie
    Hu, Qiao Hong
    Liu, Ying
    Wang, Ceng
    Wei, Ran
    Fan, Xiao Ming
    ONCOTARGET, 2017, 8 (45) : 79670 - 79679
  • [37] ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer
    van Geldermalsen, M.
    Wang, Q.
    Nagarajah, R.
    Marshall, A. D.
    Thoeng, A.
    Gao, D.
    Ritchie, W.
    Feng, Y.
    Bailey, C. G.
    Deng, N.
    Harvey, K.
    Beith, J. M.
    Selinger, C. I.
    O'Toole, S. A.
    Rasko, J. E. J.
    Holst, J.
    ONCOGENE, 2016, 35 (24) : 3201 - 3208
  • [38] Basal-like breast cancer: A review
    Treilleux, Isabelle
    Morellon-Mialhe, Blandine
    ANNALES DE PATHOLOGIE, 2009, 29 (03) : 180 - 186
  • [39] BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy
    Bouchalova, Katerina
    Svoboda, Marek
    Kharaishvili, Gvantsa
    Vrbkova, Jana
    Bouchal, Jan
    Trojanec, Radek
    Koudelakova, Vladimira
    Radova, Lenka
    Cwiertka, Karel
    Hajduch, Marian
    Kolar, Zdenek
    TUMOR BIOLOGY, 2015, 36 (06) : 4243 - 4252
  • [40] Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential
    Fermaintt, Charles S.
    Peramuna, Thilini
    Cai, Shengxin
    Takahashi-Ruiz, Leila
    Essif, Jacob Nathaniel
    Grant, Corena V.
    O'Keefe, Barry R.
    Mooberry, Susan L.
    Cichewicz, Robert H.
    Risinger, April L.
    CANCERS, 2021, 13 (11)
12345